Directly activating GIPR in hepatocytes is an unlikely explanation for the decrease in apoC-III levels with tirzepatide [91, 92]
Rotate every single time
Neuroglycopenic symptoms result from inadequate glucose supply to the central nervous system and can range from mild manifestations, such as blurred vision, lightheadedness, flushing, lethargy, and weakness, to more severe consequences, including seizures, unconsciousness, disorientation, and speech difficulties [44]
Ongoing research, such as the SUMMIT trial, is presently assessing the safety and efficacy of tirzepatide in HF patients with preserved ejection fraction (HFpEF)
For age-related macular degeneration, findings were dichotomous, suggesting a protective effect against non-exudative forms but a potential increased risk for neovascular disease